RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+1.96%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$7.51B
AUM Growth
+$7.51B
(-13%)
Cap. Flow
+$76.9M
Cap. Flow
% of AUM
1.02%
Top 10 Holdings %
Top 10 Hldgs %
57.63%
Holding
98
New
17
Increased
9
Reduced
16
Closed
9
Top Buys
| 1 |
SEPN
Septerna, Inc. Common Stock
SEPN
|
$160M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$111M |
| 3 |
Arcellx
ACLX
|
$71.8M |
| 4 |
Janux Therapeutics
JANX
|
$64.2M |
| 5 |
Ascendis Pharma
ASND
|
$55.4M |
Top Sells
| 1 |
Biogen
BIIB
|
$230M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$151M |
| 3 |
Evolent Health
EVH
|
$55.5M |
| 4 |
CG Oncology
CGON
|
$52.7M |
| 5 |
Recursion Pharmaceuticals
RXRX
|
$51.8M |
Sector Composition
| 1 | Healthcare | 98.36% |
| 2 | Financials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma
ASND
$11.8B
| $1.39B | 18.53% | 10,112,744 +402,316 | +4% | +$55.4M |
|
2
Vaxcyte
PCVX
$4B
| $711M | 9.47% | 8,689,190 | – | – |
|
|
3
Janux Therapeutics
JANX
$1.37B
| $555M | 7.39% | 10,365,652 +1,200,000 | +13% | +$64.2M |
|
4
Rhythm Pharmaceuticals
RYTM
$6.85B
| $341M | 4.53% | 6,084,412 | – | – |
|
5
Legend Biotech
LEGN
$6.41B
| $244M | 3.25% | 7,506,934 | – | – |
|
6
Edgewise Therapeutics
EWTX
$1.51B
| $238M | 3.17% | 8,909,091 | – | – |
|
7
NewAmsterdam Pharma
NAMS
$2.71B
| $227M | 3.03% | 8,845,000 +781,000 | +10% | +$20.1M |
|
8
Wave Life Sciences
WVE
$1.53B
| $225M | 3% | 18,202,009 | – | – |
|
|
9
Arcellx
ACLX
$3.85B
| $214M | 2.84% | 2,787,327 +935,848 | +51% | +$71.8M |
|
10
Avidity Biosciences
RNA
$5.99B
| $183M | 2.44% | 6,300,408 | – | – |
|
|
SEPN
11
Septerna, Inc. Common Stock
SEPN
$539M
| $160M | 2.13% | +6,995,858 | New | +$160M |
|
12
Dyne Therapeutics
DYN
$1.92B
| $150M | 2% | 6,381,144 | – | – |
|
13
Tyra Biosciences
TYRA
$675M
| $148M | 1.97% | 10,637,290 +220,681 | +2% | +$3.07M |
|
14
RxSight
RXST
$370M
| $129M | 1.71% | 3,743,018 -173,807 | -4% | -$5.98M |
|
|
BCAX
15
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $121M | 1.61% | 6,955,993 | – | – |
|
|
LENZ
16
LENZ Therapeutics
LENZ
$1.1B
| $121M | 1.61% | 4,178,823 | – | – |
|
17
ARS Pharmaceuticals
SPRY
$1.15B
| $115M | 1.52% | 10,860,977 | – | – |
|
18
89bio
ETNB
$1.34B
| $111M | 1.48% | 14,175,398 | – | – |
|
|
19
SPDR S&P Biotech ETF
XBI
$5.07B
| $111M | 1.47% | +1,228,240 | New | +$111M |
|
20
Geron
GERN
$893M
| $106M | 1.41% | 30,009,536 -2,276,219 | -7% | -$8.06M |
|
|
ARTV
21
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$76.7M
| $99.3M | 1.32% | 9,853,302 | – | – |
|
22
Axsome Therapeutics
AXSM
$6.05B
| $84.6M | 1.13% | 1,000,000 | – | – |
|
|
VRNA
23
Verona Pharma
VRNA
$9.16B
| $82.1M | 1.09% | 1,766,830 -3,242,823 | -65% | -$151M |
|
24
Day One Biopharmaceuticals
DAWN
$769M
| $72.9M | 0.97% | 5,755,577 -2,116,144 | -27% | -$26.8M |
|
25
Apogee Therapeutics
APGE
$2.17B
| $71.1M | 0.95% | 1,569,491 -392,372 | -20% | -$17.8M |
|